Philip Astley-Sparke
InvestorVenture Partner at Forbion
Boston, Massachusetts
Writes $100K – $5M checks · typically $1.5M
Find your path to Philip
27 people in our graph share verified history with Philip — schools, employers, funds. One of them is your warm intro.
About
Philip Astley-Sparke is Executive Chairman and co-founder of Replimune, a developer of oncolytic vaccines. He previously served as President and CEO of BioVex, which brought Imlygic to FDA approval in 2015 before its acquisition by Amgen in 2011, and as President of uniQure, where he established U.S. operations including a gene therapy manufacturing facility. Astley-Sparke holds a BSc in Cellular and Molecular Pathology from Bristol University, qualified as a Chartered Accountant, and has experience as a healthcare investment banker.
Skills & more
+4 more
ImmunologyMergersStrategyPharmaceutical IndustryFrom Philip's professional profile.
Colleagues at Forbion
Frequently asked questions
- Who is Philip Astley-Sparke?
- Philip Astley-Sparke is Executive Chairman and co-founder of Replimune, a developer of oncolytic vaccines. He previously served as President and CEO of BioVex, which brought Imlygic to FDA approval in 2015 before its acquisition by Amgen in 2011, and as President of uniQure, where he established U.S. operations including a gene therapy manufacturing facility. Astley-Sparke holds a BSc in Cellular and Molecular Pathology from Bristol University, qualified as a Chartered Accountant, and has experience as a healthcare investment banker.
- Where does Philip Astley-Sparke work?
- Philip Astley-Sparke is Venture Partner at Forbion.
- What check size does Philip Astley-Sparke write?
- Philip Astley-Sparke typically writes checks of $100K – $5M.